



RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE MAY 14 2003

In re application of:

BUSH *et al.*

Appl. No. 09/380,704

§ 102(e) Date: June 6, 2000

For: **Identification of Agents for Use in
the Treatment of Alzheimer's
Disease**

Confirmation No. 2953

TECH CENTER 1600/2900

Art Unit: 1647

Examiner: Bunner, B.

Atty. Docket: 0609.4350001/JAG/FRC

Seventh Supplemental Information Disclosure Statement

Director of the United States
Patent and Trademark Office
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Seventh Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Sixth Supplemental Information Disclosure Statement filed on February 15, 2001 in connection with the above-captioned application. A copy of each document is also provided.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following concise explanation of the relevance of the non-English language document, Document AI6 cited on form PTO 1449:

Document AI6, DE 40 04 978, is in the German language. An English language abstract of document AI6 is attached as Document AS42.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates

should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.


This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application.

Attached is our PTO-2038 Credit Card Payment Form in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,


STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Frank R. Cottingham
Attorney for Applicants
Registration No. 50,437

Date: MAY 9, 2003

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600



RECEIVED

Page 1 of 3

FORM PTO-1449

ATTY. DOCKET NO.
0609.4350001/JAG/FRCAPPLICATION NO.
09/380,704

MAY 14 2003

SEVENTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTAPPLICANT
BUSH et al.§ 102(e) Date:
June 6, 2000GROUP
1647

TECH CENTER 1600/2600

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH2	4,419,365	12/06/1983	McLachlan			12/21/1981

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AI6	DE 40 04 978 A1	08/22/1991	Germany			Yes No
	AJ6	WO 94/27594 A2	12/08/1994	WIPO			Yes No
	AK6	WO 96/39144 A1	12/12/1996	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS	40	BIOMOL Product Data for TPEN, Catalog No. AP-300, Lot No. P3707, BIOMOL Research Laboratories, Inc. Plymouth Meeting, PA (July 2002)
	AT	40	Cardelli, M., et al., "Chelation Therapy. Unproved Modality in the Treatment of Alzheimer-Type Dementia," J. Am. Geriatr. Soc. 33:548-551, Blackwell Science (1985)


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\\ODMA\MHODMA\SKGF_DC1\111719;1

SKGF Rev. 1/95



RECEIVED

Page 2 of 3

MAY 14 2003

FORM PTO-1449 <u>SEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 0609.4350001/JAG/FRC	APPLICATION NO. 09/380,704
	APPLICANT BUSH et al.	
	§ 102(e) Date: June 6, 2000	
	GROUP 1647	

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA3	5,310,936	05/10/1994	Regtop et al.			01/15/1992
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AI7	WO 97/01559 A1	01/16/1997	WIPO			Yes No
	AJ						Yes No
	AK						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>41</u>	Ishii, T., and Bannai, S., "The Synergistic Action of the Copper Chelator Bathocuproine Sulphonate and Cysteine in Enhancing Growth of L1210 Cells In Vitro," <i>J. Cell. Physiol.</i> 125:151-155, Alan R. Liss, Inc. (1985)
AS	<u>41</u>	Kruck, T.P.A., et al., "Suppression of deferoxamine mesylate treatment-induced side effects by coadministration of isoniazid in a patient with Alzheimer's disease subject to aluminum removal by ionspecific chelation," <i>Clin. Pharmacol. Ther.</i> 48:439-446, Mosby-Year Book (1990)
AT	<u>41</u>	<i>The Merck Index: An encyclopedia of chemicals, drugs, and biologicals</i> , 11 th edition, Budavari, S., et al., eds., Merck & Co., Inc., Rahway, N.J., p. 9586 (1989)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED
Page 3 of 3

FORM PTO-1449

SEVENTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
0609.4350001/JAG/FRCAPPLICATION NO.
09/380,704

MAY 14 2003

APPLICANT
BUSH et al.§ 102(e) Date:
June 6, 2000GROUP
1647

TECH CENTER 1600/29C

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AI						Yes No
	AJ						Yes No
	AK						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	42	Van Reyk, D.M., and Dean, R.T., "The Iron-selective Chelator Desferal Can Reduce Chelated Copper," <i>Free Radic. Res.</i> 24:55-60, Harwood Academic Publishers GmbH (January 1996)
	AS	42	Dialog File 351, Accession No. 8749401, Derwent WPI English language abstract for DE 4004978.
	AT		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.